PPARG and Parkinson disease: Indeed PPARγ agonists show neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD, with amelioration of MPTP-induced dopaminergic neuron loss and reduced gliosis (Breidert et al., 2002; Dehmer et al., 2004; Schintu et al., 2009; Martin et al., 2012).